Alnylam Pharmaceuticals Inc. (ALNY)
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at UBS Global Healthcare Conference 2025 Transcript
Alnylam Pharmaceuticals, Inc. ( ALNY ) UBS Global Healthcare Conference 2025 November 10, 2025 10:15 AM EST Company Participants Jeffrey Poulton - CFO & Executive VP John Vest - Senior Vice President of Clinical Research Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division All right. Good day, everybody.
Alnylam Pharmaceuticals: Q3 Earnings Review - A Sensational Year Reaches Its Peak
Alnylam Pharmaceuticals, Inc. delivered strong Q3 results, driven by Amvuttra's success in ATTR-CM, with total revenues soaring to $1.25 billion. ALNY's market cap surged to $59B as Amvuttra outperformed rivals, but valuation appears stretched at a forward P/S ratio of ~16x. The pipeline is robust, with promising candidates in cardiovascular, rare disease, and metabolic indications, and a $2.7B cash position.
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
Alnylam's Q3 earnings and revenues surge past forecasts, powered by booming Amvuttra sales and a key milestone payment from Roche.
Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $2.9 per share, beating the Zacks Consensus Estimate of $1.67 per share. This compares to a loss of $0.5 per share a year ago.
Exploring Analyst Estimates for Alnylam (ALNY) Q3 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of Alnylam (ALNY) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You Looking for a Top Momentum Pick? Why Alnylam Pharmaceuticals (ALNY) is a Great Choice
Does Alnylam Pharmaceuticals (ALNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why Alnylam Pharmaceuticals (ALNY) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
ALNY's portfolio of rare disease and cardiovascular drugs is boosting revenues and reducing reliance on Amvuttra.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Citi's Biopharma Back To School Conference Prepared Remarks Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Citi's Biopharma Back to School Conference September 3, 2025 1:45 PM EDT Company Participants Jeffrey Poulton - CFO & Executive VP Kevin Fitzgerald - Executive VP, Chief Scientific Officer and Head of Early Research & Early Development Conference Call Participants David Lebowitz - Citigroup Inc., Research Division Presentation David Lebowitz Research Analyst Thank you all. Welcome all again to the 2025 Citi Biopharma Conference in Boston.
Alnylam Pharmaceuticals: Amvuttra's Launch And Ongoing Clinical Progress Are Positives
Alnylam's strong clinical productivity and commercial execution continue to support my view that it's one of the best all-around biotechs, with a robust revenue and earnings outlook. Amvuttra's TTR-CM launch has exceeded initial expectations, driving significant revenue growth and reinforcing its long-term potential in the TTR space. While KARDIA-3 results for zilebesiran were mixed, the drug still holds multibillion-dollar potential, and Alnylam's pipeline remains deep and promising.
